Product
Tesamorelin
Aliases
Egrifta
Name
EGRIFTA SV
INN Name
tesamorelin
FDA Approved
Yes
5 clinical trials
1 organization
11 indications
1 document
Indication
LipodystrophyIndication
HIV InfectionsIndication
HIV Lipodystrophy SyndromeIndication
Growth Hormone DeficiencyIndication
Body CompositionIndication
Mild Cognitive ImpairmentIndication
Nonalcoholic Fatty Liver DiseaseIndication
ObesityIndication
AbdominalIndication
Fatty LiverIndication
Peripheral Nerve InjuriesClinical trial
A Multicenter, Double-blind, Randomized, Placebo-controlled Extension Study Assessing the Efficacy and Long-term Safety of a 2 mg Dose of TH9507, a GHRH Analog, in HIV Subjects With Excess Abdominal Fat AccumulationStatus: Completed, Estimated PCD: 2008-10-01
Clinical trial
Body Composition and Adipose Tissue in HIV Lipodystrophy: Effects of Tesamorelin TherapyStatus: Recruiting, Estimated PCD: 2025-04-30
Clinical trial
Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected PersonsStatus: Completed, Estimated PCD: 2023-10-15
Clinical trial
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular RiskStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Tesamorelin Therapy to Enhance Axonal Regeneration, Minimize Muscle Atrophy, and Improve Functional Outcomes Following Peripheral Nerve InjuryStatus: Recruiting, Estimated PCD: 2025-12-01
Document
DailyMed Label: EGRIFTA SVOrganization
Theratechnologies Inc.